ArticleFrontiers in microbiology2025
Sitagliptin ameliorates microbial dysbiosis and enhances gut barrier integrity in streptozotocin-induced type 2 diabetic rats.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The gut-pancreas axis: microbial dysbiosis as a pathogenic driver of diabetes and pancreatic cancer.Medical oncology (Northwood, London, England) · 2026Review
- Protective Effects of Sitagliptin on Dextran Sulfate Sodium-Induced Colitis via Modulation of Inflammatory and Oxidative Stress.Medicina (Kaunas, Lithuania) · 2026Article
- Dietary polyphenols maintain human health through modulation of gut microbiota.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has demonstrated efficacy in the management of type 2 diabetes mellitus (T2DM). This study aimed to investigate the effects of sitagliptin on gut microbial composition and gut barrier integrity in a streptozotocin (STZ)-induced rat model of T2DM. Methods: Sprague-Dawley rats were randomly divided into four groups ( Result: Alpha index metrics, including observed feature number and Shannon index, were significantly decreased in the T2DM group compared to the ND group. Sitagliptin treatment led to a significant restoration of these indices. Principal coordinate analysis based on Bray-Curtis distances revealed distinct clustering between the ND and T2DM groups, with sitagliptin shifting the microbial profile of diabetic rats toward that of healthy controls. Sitagliptin treatment increased the relative abundance of Conclusion: Sitagliptin effectively ameliorates gut microbial dysbiosis and restores intestinal barrier function in STZ-induced T2DM rats. These findings provide novel insights into the gut-related therapeutic effects of sitagliptin and underscore its potential in restoring gut homeostasis in T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.